ABOUT PROVISTA
Provista Diagnostics is focused on developing world-class diagnostics for indications in breast and gynecological cancers. When used in combination with standard of care, Provista's blood-based diagnostic tests provide real-time actionable results to improve the accuracy of cancer detection.
Read More
SCIENCE & TECHNOLOGY
Provista’s proprietary ProteoMark® Technology combines multiple Serum Protein Biomarkers and Tumor Associated Autoantibodies, with patient clinical data, to yield highly accurate diagnostic tests for women’s cancers.
Read More
DIAGNOSTIC PIPELINE
Provista is developing a robust pipeline of diagnostic blood tests to address unmet needs in women’s cancers including breast, ovarian, endometrial and HPV-associated cancers.
Read More
Diagnostic Dilemma
Dense breast tissue is normal and common among woman and it refers to the appearance of breast tissue on a mammogram. Dense tissue appears white on a mammogram similar to both benign and cancerous lumps leading to both false negative and false positive results.
Read More

NEWS

Sign Up for E-News
July 28, 2016

Jul 28, 2016

Provista Diagnostics Appoints Judith K. Wolf, M.D., as Chief Medical Officer New York – July 28, 2016 – Provista Diagnostics Inc., a company developing and commercializing protein-based diagnostic, prognostic and monitoring tests for cancers affecting women, has appointed Judith K. Wolf, MD, as Chief Medical Officer. In this role, Dr. […]
July 7, 2016

Jul 7, 2016

Breast Cancer Blood Test Now Accessible Under Health Benefits for Millions of Women in the U.S. Provista Diagnostics Announces 13 Signed Agreements with Third Party Administrator Networks New York – July 7, 2016 – Provista Diagnostics, a private company developing and commercializing protein-based diagnostic, prognostic and monitoring tests for cancers […]
June 2, 2016

Jun 2, 2016

Provista Diagnostics Announces Positive Trial Results Assessing the Use of Videssa® Breast to Detect Breast Cancer Findings from Trial’s Second Cohort Replicate Prior Results New York – June 2, 2016 – Provista Diagnostics, a company developing and commercializing proteomic-based diagnostic, prognostic and monitoring tests for cancers affecting women, today announced […]